Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

34.66
-0.1046-0.30%
Post-market: 34.760.1046+0.30%16:10 EDT
Volume:188
Turnover:7K
Market Cap:16.29M
PE:- -
High:34.66
Open:34.76
Low:34.66
Close:34.76
52wk High:37.90
52wk Low:30.79
Shares:469.95K
Float Shares:469.95K
Volume Ratio:0.58
T/O Rate:0.04%
Dividend:0.41
Dividend Rate:1.18%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001

TIPRANKS
·
Sep 28

JPMorgan Adjusts Price Target on Eli Lilly to $1,500 From $1,400, Maintains Overweight Rating

MT Newswires Live
·
Sep 28

Dezhan Healthcare's Subsidiary Receives FDA Approval for Clinical Trial of Innovative Drug WYY026B Injection

Stock News
·
Sep 28

Eli Lilly's Olumiant Gets FDA Approval for Severe Alopecia Areata in Adolescents

MT Newswires Live
·
Sep 28

Healthcare Shows Resilience! Pharma ETF Huabao (562050) Rises Against the Market, Livzon Pharmaceutical Group Hits Limit Up! Medical Devices Show Localized Strength, Mindray and United Imaging Advance Together

Deep News
·
Sep 28

Hutchmed initiates Phase Ia part of trial of HMPL-A830

TIPRANKS
·
Sep 28

Nektar selloff on trial brings ‘strong entry point,’ says BTIG

TIPRANKS
·
Sep 28

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

TIPRANKS
·
Sep 27

US FDA Approves AbbVie's Drug for Parkinson's Disease

Reuters
·
Sep 26

US FDA - Approves Juvmo (Tavapadon) for Parkinson’s Disease in Adults on Sept 25, 2026

THOMSON REUTERS
·
Sep 26

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 26

Eli Lilly Gets Expanded Label Approval from FDA for Alopecia Drug

Dow Jones
·
Sep 26

FDA Approves Lilly's Olumiant (Baricitinib) for Pediatric Patients 12 Years of Age and Older with Severe Alopecia Areata

THOMSON REUTERS
·
Sep 26

ADARx Pharmaceuticals Shares Soar in NASDAQ Debut After Upsized IPO

Reuters
·
Sep 26

Novartis AG Rises Friday, Outperforms Market

Dow Jones
·
Sep 26

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Johnson & Johnson Says Tremfya Significantly Improves Axial Psoriatic Arthritis Symptoms in Phase 4 Study

MT Newswires Live
·
Sep 25

Novo Bets on Next Chapter While Eli Lilly Extends Its GLP-1 Dominance

Deep News
·
Sep 25

Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study

TIPRANKS
·
Sep 25